Fernanda Viana de Almeida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fernanda Viana de Almeida has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Allan Michael de Lima
Universidade de Gurupi
1 shared publication - Fernanda Duarte Maciel
Universidade de Gurupi
1 shared publication - Fernanda Paim Braga da Silva
Universidade de Gurupi
1 shared publication - Gustavo Soares Lobo
Universidade de Gurupi
1 shared publication - João Paulo Silva Azeredo
Universidade de Gurupi
1 shared publication - João Paulo de Jesus Soares Leal
Universidade de Gurupi
1 shared publication
Latest Publications
- Open Access
- 13 January 2023
- Published by Research, Society and Development in Research, Society and Development
- Vol. 12 (2)
Segurança e eficácia do dimesilato de lisdexanfetamina em transtorno de déficit de atenção e hiperatividade: uma revisão literária
Attention Deficit Hyperactivity Disorder (ADHD) is a neurological disorder that is associated with poor brain performance. Individuals with ADHD have dyslexia, a certain impulsiveness and difficulty concentrating, resulting in poor school development. Taking into account, about 2.5 million new cases are declared per year in Brazil, whether due to real necessity or mere mediocrity of the diagnosis. Lisdexamfetamine methylphenidate is the main representative of a new class of long-acting agents for the treatment of ADHD, in current scenarios it has been the drug traditionally used as first choice for the treatment of children and adolescents with ADHD. Therefore, the general objective of this study was to analyze the effects that lisdexamfetamine dimesylate has for individuals with ADHD. In the methodology, a literature review was carried out, including studies in Portuguese and published between 2017 and 2022. Data collection took place in PubMed, LILACS, Scielo and Google Scholar databases. In the results, the safety and efficacy of lisdexamfetamine dimesylate for patients with ADHD proved to be effective and positive. In the studies found, it was understood that this drug has as its mechanism of action the blockade of the reuptake of the neurotransmitter dopamine and the stimulus to its production and noradrenaline. This action is what makes the stimulant of this medicine effective.
- 13 January 2023
- Published by Research, Society and Development in Research, Society and Development
- Vol. 12 (2)
Open AccessSegurança e eficácia do dimesilato de lisdexanfetamina em transtorno de déficit de atenção e hiperatividade: uma revisão literária
Attention Deficit Hyperactivity Disorder (ADHD) is a neurological disorder that is associated with poor brain performance. Individuals with ADHD have dyslexia, a certain impulsiveness and difficulty concentrating, resulting in poor school development. Taking into account, about 2.5 million new cases are declared per year in Brazil, whether due to real necessity or mere mediocrity of the diagnosis. Lisdexamfetamine methylphenidate is the main representative of a new class of long-acting agents for the treatment of ADHD, in current scenarios it has been the drug traditionally used as first choice for the treatment of children and adolescents with ADHD. Therefore, the general objective of this study was to analyze the effects that lisdexamfetamine dimesylate has for individuals with ADHD. In the methodology, a literature review was carried out, including studies in Portuguese and published between 2017 and 2022. Data collection took place in PubMed, LILACS, Scielo and Google Scholar databases. In the results, the safety and efficacy of lisdexamfetamine dimesylate for patients with ADHD proved to be effective and positive. In the studies found, it was understood that this drug has as its mechanism of action the blockade of the reuptake of the neurotransmitter dopamine and the stimulus to its production and noradrenaline. This action is what makes the stimulant of this medicine effective.